While optimal medicamentous therapy is important in the treatment of patients with stable coronary artery disease (CAD), in some cases, prognostic and symptomatic benefit can only be achieved with myocardial revascularization procedures such as coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI). However, mounting evidence with increasing use of these procedures shows that they may cause irreversible myocardial injuries despite successful myocardial revascularization. This paradox is referred to as ischemic-reperfusion injury and is due to the formation of free oxygen radicals in response to reperfusion of the ischemic myocardium. It induces an increase in biomarkers of necrosis, which has been reported to be associated with a high risk of death.1,2
One of the promising ways to provide cardioprotection in patients undergoing PCI and CABG may be the use of the antianginal drug trimetazidine. Trimetazidine is known to exert its anti-ischemic effect by providing the necessary ATP in the cardiomyocytes, thus promoting a decrease in intracellular acidosis and preventing intracellular calcium overload.
Prof Lopatin from Russia led two studies, including patients who were undergoing PCI or CABG, to identify potential short- and long-term beneficial effects of administration of trimetazidine MR at a dose of 70 mg/day for 2 weeks prior to the procedures, and during the 3 following years.
In the study considering angina patients who underwent CABG,…
Prof Lopatin showed that addition of trimetazidine MR
– for 3 years leads to a significantly more pronounced increase in left ventricular ejection fraction, meaning that trimetazidine MR enables a patient’s heart to continue contracting properly, which is essential to preserve quality of life. Other results in the study show that trimetazidine MR also provides higher exercise tolerance and a significant reduction in recurrence of angina pectoris.
– In addition to that, administration of trimetazidine MR lowers levels of creatine kinase-MB isoenzyme (CK-MB) in the early postoperative period, showing that trimetazidine MR protects the myocardium and decreases myocardial damage during revascularization procedures.
In the study considering angina patients who underwent PCI,…
Prof Lopatin showed that addition of trimetazidine MR:
– for 3 years leads to a significant reduction in the rate of hospitalization for acute coronary syndromes, showing that trimetazidine MR has a strong cardioprotective effect. Other results show that trimetazidine significantly reduces repeat procedures of coronary revascularization, and that it also significantly increases left ventricular ejection fraction and exercise tolerance.
– In addition to that, administration of trimetazidine MR lowers frequency of arrhythmias in the early postoperative period.
During the last ESC Congress, Prof Lopatin went further and presented his 6-year long-term data with trimetazidine MR in post–myocardial infarction patients with stable angina and heart failure. These results were totally in line with the 2 previous studies, showing that long-term prescription of trimetazidine MR:
– significantly reduces the rate of MACE (cardiac death, nonfatal myocardial infarction, acute stroke, need for coronary revascularization, hospitalization for unstable angina or heart failure), and
– significantly reduces all-cause mortality.
Prof Lopatin’s studies have highlighted the cardioprotective effect of trimetazidine MR, both in the short-term during revascularization and in the long-term (up to 6 years).
Download the slide set
- Thiazide-Like/calcium channel blocker agents: a major combination for hypertension management
- Brazilian guidelines acknowledge perindopril in coronary artery disease (CAD) patients
- Can we prevent stent restenosis after coronary stent implantation?
- Survival benefits of blood pressure treatment persist many years after
- Is it useful to control blood pressure faster in hypertensive patients?
- Blood pressure and chronic heart failure management
- Central blood pressure: what do we really know today?
- “…physicians may need to readdress their approach to antihypertensive treatment
- Heart failure and co-morbidities
- New study comparing ACE-inhibitors to ARBs on 5-year survival after acute myocardial infarction
- A Controlled Trial of Renal Denervation for Resistant Hypertension
- Effects of combination of Perindopril, Indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus
- Can we improve the management of angina patients after percutaneous coronary intervention?
- Evidence for the effective use of medications and management to improve survival in heart failure patients
- Can we protect patients undergoing percutaneous coronary intervention better?
- A new meta-analysis comparing ACE inhibitors vs ARBs on cardiovascular events in the diabetic population (1)
- Renal denervation for resistant hypertension
- Pharmacological treatment in post-PCI patients with persistent angina
- Overcoming the challenge of blood pressure control in prediabetic and diabetic patients: PICASSO T2D Study
- Evidence of heart rate reduction on modulation of the collateral circulation in patients with stable coronary artery disease